PYPD
PolyPid Ltd.
Biotechnology
Market Cap$81M
5Y Perf.-99.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PYPD vs HALO
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+143.2%
PYPD vs HALO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PYPD | HALO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $81M | $7.68B |
| Revenue (TTM) | $0.00 | $1.40B |
| Net Income (TTM) | $-34M | $317M |
| Gross Margin | — | 81.9% |
| Operating Margin | — | 58.4% |
| Forward P/E | — | 8.1x |
| Total Debt | $3M | $0.00 |
| Cash & Equiv. | $6M | $134M |
PYPD vs HALO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PYPD
HALO
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| PolyPid Ltd. (PYPD) | 100 | 0.8 | -99.2% |
| Halozyme Therapeuti… (HALO) | 100 | 243.2 | +143.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PYPD vs HALO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. PolyPid Ltd. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PYPD
PolyPid Ltd.
The Growth Play
PYPD is the clearest fit if your priority is growth exposure.
- EPS growth 57.4%
- +57.3% vs HALO's -7.1%
Best for: growth exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.56
- 5.7% 10Y total return vs PYPD's -99.2%
- Lower volatility, beta 0.56, current ratio 4.66x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HALO | 37.6% revenue growth vs PYPD's -2.9% |
| Quality / Margins | HALO | 22.7% margin vs PYPD's -3.1% |
| Stability / Safety | HALO | Beta 0.56 vs PYPD's 1.11 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PYPD | +57.3% vs HALO's -7.1% |
| Efficiency (ROA) | HALO | 12.5% ROA vs PYPD's -153.2%, ROIC 73.4% vs -5.5% |
PYPD vs HALO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PYPD vs HALO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGPYPD
PYPDPolyPid Ltd.
1leads
HALOHalozyme Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs PYPDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
PYPD2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
HALO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
HALO and PYPD operate at a comparable scale, with $1.4B and $0 in trailing revenue.
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.4B |
| EBITDAEarnings before interest/tax | -$15M | $945M |
| Net IncomeAfter-tax profit | -$34M | $317M |
| Free Cash FlowCash after capex | $0 | $645M |
| Gross MarginGross profit ÷ Revenue | — | +81.9% |
| Operating MarginEBIT ÷ Revenue | — | +58.4% |
| Net MarginNet income ÷ Revenue | — | +22.7% |
| FCF MarginFCF ÷ Revenue | — | +46.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +51.6% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -2.1% |
Insufficient data to determine a leader in this category.
Valuation Metrics
PYPD leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| Market CapShares × price | $81M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $77M | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.12x | 25.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.09x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.11x |
| EV / EBITDAEnterprise value multiple | — | 8.34x |
| Price / SalesMarket cap ÷ Revenue | — | 5.50x |
| Price / BookPrice ÷ Book value/share | 6.61x | 165.47x |
| Price / FCFMarket cap ÷ FCF | — | 11.91x |
PYPD leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-3 for PYPD. On the Piotroski fundamental quality scale (0–9), HALO scores 5/9 vs PYPD's 3/9, reflecting solid financial health.
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| ROE (TTM)Return on equity | -3.1% | +6.5% |
| ROA (TTM)Return on assets | -153.2% | +12.5% |
| ROICReturn on invested capital | -5.5% | +73.4% |
| ROCEReturn on capital employed | -2.4% | +38.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.25x | — |
| Net DebtTotal debt minus cash | -$4M | -$134M |
| Cash & Equiv.Liquid assets | $6M | $134M |
| Total DebtShort + long-term debt | $3M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -27.47x | 46.08x |
HALO leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
HALO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,704 today (with dividends reinvested), compared to $168 for PYPD. Over the past 12 months, PYPD leads with a +57.3% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs PYPD's -29.1% — a key indicator of consistent wealth creation.
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| YTD ReturnYear-to-date | +2.0% | -7.3% |
| 1-Year ReturnPast 12 months | +57.3% | -7.1% |
| 3-Year ReturnCumulative with dividends | -64.3% | +115.3% |
| 5-Year ReturnCumulative with dividends | -98.3% | +37.0% |
| 10-Year ReturnCumulative with dividends | -99.2% | +570.7% |
| CAGR (3Y)Annualised 3-year return | -29.1% | +29.1% |
HALO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PYPD and HALO each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than PYPD's 1.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PYPD currently trades 86.6% from its 52-week high vs HALO's 79.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 0.56x |
| 52-Week HighHighest price in past year | $5.12 | $82.22 |
| 52-Week LowLowest price in past year | $2.44 | $47.50 |
| % of 52W HighCurrent price vs 52-week peak | +86.6% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 50.3 | 52.4 |
| Avg Volume (50D)Average daily shares traded | 51K | 1.4M |
Evenly matched — PYPD and HALO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PYPDPolyPid Ltd. | HALOHalozyme Therapeu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $78.33 |
| # AnalystsCovering analysts | — | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). PYPD leads in 1 (Valuation Metrics). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 2 of 6 categories
Loading custom metrics...
PYPD vs HALO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PYPD or HALO a better buy right now?
Halozyme Therapeutics, Inc.
(HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Halozyme Therapeutics, Inc. (HALO) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PYPD or HALO?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +37. 0%, compared to -98. 3% for PolyPid Ltd. (PYPD). Over 10 years, the gap is even starker: HALO returned +570. 7% versus PYPD's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PYPD or HALO?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus PolyPid Ltd. 's 1. 11β — meaning PYPD is approximately 100% more volatile than HALO relative to the S&P 500.
04Which is growing faster — PYPD or HALO?
On earnings-per-share growth, the picture is similar: PolyPid Ltd.
grew EPS 57. 4% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PYPD or HALO?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus 0. 0% for PolyPid Ltd. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for PYPD. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PYPD or HALO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PYPD or HALO better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, PYPD: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PYPD and HALO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PYPD is a small-cap quality compounder stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.